



ASX Release

8 November 2023

Receipt of R&D Tax Incentive Rebate for FY23

Melbourne, Australia; Acrux Limited (ASX:ACR) is pleased to announce receipt of \$2,868,795 from the Australian Tax Office in relation to its R&D Tax Incentive Rebate, which includes eligible overseas expenditure, for the 2022/2023 financial year.

The R&D Tax Incentive is an Australian Federal Government program under which companies may receive cash refunds for eligible research and development expenditure.

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Drawing on 25 years of experience and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au